Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepcidin-guided prediction of iron therapy response in active inflammatory bowel disease
NL-OMON54041Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ferrous fumarate, ferric maltol and Iron in iron deficiency anemia (IDA) (3 arms), sponsored by Leiden University Medical Center. Primary endpoints: Predictive value of baseline hepcidin for response to iron therapy, Response in iron deficiency anemia and 1 more. Started Jun 2022; status: completed.
02
Drugs
ferrous fumarateferric maltolIron
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON54041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54041.